Similarly, in HAVEN 2, pediatric patients with hemophilia A and FVIII inhibitors who received weekly emicizumab achieved an even lower ABR [0.3], with a large proportion reporting zero treated bleeds [77%] [15, 21]. Here, F8 is linked to hemophilia A.